Dr. Offmanは、20年以上にわたる医薬品開発の経験を有しています。2017年にサターラに入社し、サターラの臨床薬理＆トランスレーショナル・メディシングループでトランスレーショナル薬物動態および薬力学の業務を率いています。Dr. Offman has supported the development of several oncology products including Asparlas (calaspargase pegol), Oncaspar (pegasparaginase) and brigatinib (Alunbrig), and was instrumental in the approval of RedHill Biopharma’s Talicia for H. pylori infection. Prior to joining Certara, Dr. Offman was responsible for clinical pharmacology and pharmacometrics at Celerion, leading study design, data analysis and interpretation for clinical pharmacology studies including first-in-human, drug-drug interactions, mass balance and special population trials. Prior to joining Certara, Dr. Offman oversaw biopharmaceutics and scientific affairs for Genpharm, a subsidiary of Merck KGaA as well as Mylan. Additionally, as a clinical pharmacologist, Dr. Offman has supported development and approval of Epanova (Omthera), XHANCE (Optinose) and Austedo (Auspex).

Dr. Offman obtained a PhD at the University of Waterloo (Waterloo, Canada) in model-based drug development with a particular focus in physiologically and population based pharmacokinetic modelling of subcutaneously administered large molecules. Dr. Offman is a licensed pharmacist and completed a residency in clinical pharmacy at the London Healthy Sciences Centre (Ontario, Canada) and a MSc in Clinical Pharmacology from Western University in Ontario, Canada. Dr. Offman is a holder of a patent and has co-authored over 50 abstracts and peer-reviewed manuscripts.